HOOK - HOOKIPA Pharma slumps on Phase 1/2 data for lead cancer therapies

HOOKIPA Pharma ([[HOOK]] -7.1%) has sharply today after announcing an abstract that includes data for its lead assets HB-201 and HB-202 in advanced Human Papillomavirus 16-positive (HPV16+) cancers.The abstract will be part of an oral presentation scheduled for June 07 at the upcoming 2021 American Society of Clinical Oncology ((ASCO)) Annual Meeting.The two arenaviral therapeutics are undergoing a phase 1/2 open-label trial involving patients with treatment-refractory HPV16+ cancers who progressed despite the standard of care.The primary endpoint of Phase 1 was the recommended Phase 2 dose based on safety and tolerability. As of January 2021, 25 patients were enrolled with a median of three previous cancer treatments.Treatment-emergent adverse events (TEAEs) that were generally mild or moderate occurred in 21 patients (84%), the abstract says.Events related to the drug were reported in 14 patients (56%). Serious TEAEs were found in 6 patients (24%). One patient with “hemorrhagic shock deemed unrelated to study drug,” according to investigators,

For further details see:

HOOKIPA Pharma slumps on Phase 1/2 data for lead cancer therapies